Top

Published in:

01-02-2018 | Original Article

Early-phase myocardial uptake intensity of ^99mTc-HMDP vs ^99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis

Authors: Mukedaisi Abulizi, MD, Anne-Ségolène Cottereau, MD, Aziz Guellich, PhD, Stéphanie Vandeventer, MD, Arnault Galat, MD, Axel Van Der Gucht, MD, Violaine Plante-Bordeneuve, MD, PhD, Jean-Luc Dubois-Randé, MD, PhD, Diane Bodez, MD, Jean Rosso, MD, Thibaud Damy, MD, PhD, Emmanuel Itti, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 1/2018

Abstract

Background

This study sought to compare the intensity of early-phase myocardial uptake of two phosphonate-based radiotracers, ^99mTc-hydroxymethylene diphosphonate (HMDP) and ^99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD), in patients with hereditary transthyretin-related cardiac amyloidosis (TTR-CA).

Methods

Six patients with biopsy-proven diagnosis of TTR-CA and characteristic amyloid fibril composition underwent early-phase ^99mTc-HMDP myocardial scintigraphy as part of their routine workup; they were later assessed by ^99mTc-DPD scintigraphy after having signed informed written consent. Heart-to-mediastinum-ratio was measured at both time points as well as regional distribution on 17-segment analysis.

Results

All patients had an H/M ratio >1.28 on both imaging. ^99mTc-DPD uptake was slightly higher than ^99mTc-HMDP uptake in 3 patients, but no statistical difference was found (P = 0.13). Regional distribution of the two radiotracers was well correlated on bull’s eyes analysis, with only slight underestimation of ^99mTc-DPD uptake in the anterior/apical segments, compared with ^99mTc-HMDP.

Conclusion

^99mTc-HMDP and ^99mTc-DPD show comparable myocardial uptake intensity on early-phase scintigraphy and can be used alternatively for the diagnosis of TTR-CA.

Available only for authorised users

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–96.CrossRefPubMed

Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 2014;35:E2403–12.CrossRefPubMed

Coelho T, Maurer MS, Suhr OB. THAOS—the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63–76.CrossRefPubMed

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404–12.CrossRefPubMed

Galat A, Van der Gucht A, Guellich A, Bodez D, Cottereau AS, Guendouz S et al. Early Phase ⁹⁹Tc-HMDP Scintigraphy for the Diagnosis and Typing of Cardiac Amyloidosis. JACC Cardiovasc Imaging 2016;in press.

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using ^99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076–84.CrossRefPubMed

Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99 m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659–70.CrossRefPubMed

Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014;15:1289–98.CrossRefPubMed

Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 2014;21:35–44.CrossRefPubMed

10.

Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210–20.CrossRefPubMed

11.

Castano A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A et al. Serial scanning with technetium pyrophosphate (^99mTc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol 2015.

12.

Worsley DF, Lentle BC. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals. J Nucl Med 1993;34:1612–5.PubMed

13.

Kulhanek J, Movahed A. Uptake of technetium 99m HDP in cardiac amyloidosis. Int J Cardiovasc Imaging 2003;19:225–7.CrossRefPubMed

14.

Van Der Gucht A, Galat A, Rosso J, Guellich A, Garot J, Bodez D, et al. [¹⁸F]NaF PET/CT imaging in cardiac amyloidosis. J Nucl Cardiol 2016;23:846–9.CrossRef

15.

Kula RW, Engel WK, Line BR. Scanning for soft-tissue amyloid. Lancet 1977;1:92–3.CrossRefPubMed

16.

Bodez D, Ternacle J, Guellich A, Galat A, Lim P, Radu C et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid 2016;23:158–67.CrossRefPubMed

17.

Germano G, Kavanagh PB, Waechter P, Areeda J, Van Kriekinge S, Sharir T, et al. A new algorithm for the quantitation of myocardial perfusion SPECT. I: technical principles and reproducibility. J Nucl Med 2000;41:712–9.PubMed

18.

Buroni F, Persico MG, Lodola L, Concardi M, Aprile C. In vitro study: binding of ^99mTc-DPD to synthetic amyloid fibrils. Curr Issues Pharm Med Sci 2015;28:231–5.

19.

Lakkis NM, He ZX, Verani MS. Diagnosis of coronary artery disease by exercise thallium-201 tomography in patients with a right ventricular pacemaker. J Am Coll Cardiol 1997;29:1221–5.CrossRefPubMed

Title: Early-phase myocardial uptake intensity of 99mTc-HMDP vs 99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis
Authors: Mukedaisi Abulizi, MD
Anne-Ségolène Cottereau, MD
Aziz Guellich, PhD
Stéphanie Vandeventer, MD
Arnault Galat, MD
Axel Van Der Gucht, MD
Violaine Plante-Bordeneuve, MD, PhD
Jean-Luc Dubois-Randé, MD, PhD
Diane Bodez, MD
Jean Rosso, MD
Thibaud Damy, MD, PhD
Emmanuel Itti, MD, PhD
Publication date: 01-02-2018
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 1/2018
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-016-0707-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Early-phase myocardial uptake intensity of ^99mTc-HMDP vs ^99mTc-DPD in patients with hereditary transthyretin-related cardiac amyloidosis

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Case Presentation Commentary on “Deciding wisely: A case for an effective use of myocardial perfusion imaging”

Announcement: New initiative ‘case presentation corner’

Measurement of MBF by PET is ready for prime time as an integral part of clinical reports in diagnosis and risk assessment of patients with known or suspected CAD-PRO

Reasons and implications of agreements and disagreements between coronary flow reserve, fractional flow reserve, and myocardial perfusion imaging

Routine evaluation of left ventricular function using CZT-SPECT, with low injected activities and limited recording times

No fire in the belly: SPECT diagnosis of ruptured abdominal aortic aneurysm

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page